Ken Griffin Atara Biotherapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$0.44 - $1.22 $3,916 - $10,858	8,900 Added 93.68%	18,400 $12,000
Q4 2023 Feb 14, 2024	SELL	$0.23 - $1.74 $175,628 - $1.33 Million	-763,600 Reduced 98.77%	9,500 $4,000
Q3 2023 Nov 14, 2023	BUY	$1.41 - $2.31 $6,768 - $11,088	4,800 Added 0.62%	773,100 $1.14 Million
Q2 2023 Aug 14, 2023	SELL	$1.5 - $3.04 $24,600 - $49,856	-16,400 Reduced 2.09%	768,300 $1.24 Million
Q1 2023 May 15, 2023	SELL	$2.8 - $5.46 $48,720 - $95,004	-17,400 Reduced 2.17%	784,700 $2.28 Million
Q4 2022 Feb 14, 2023	BUY	$2.85 - $5.18 $2.25 Million - $4.09 Million	789,500 Added 6265.87%	802,100 $2.63 Million
Q3 2022 Nov 14, 2022	SELL	$2.85 - $8.73 $9,120 - $27,936	-3,200 Reduced 20.25%	12,600 $48,000

2.89M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.08B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.